LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Accueil・Liste d'Actions・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Fermé

13.17 0.38

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

12.93

Max

13.33

Chiffres clés
By Trading Economics
Revenu	-6.4M -20M
Ventes	-807K 71M
BPA	-0.13
Marge bénéficiaire	-28.24
Employés	624
EBITDA	-7.9M -14M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+47.91% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-150M 2.2B
Ouverture précédente	12.79
Clôture précédente	13.17

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

8.81 / 10.18 Support & Résistance

Adaptive Biotechnologies Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 mai 2026, 22:44 UTC

Acquisitions, Fusions, Rachats

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 mai 2026, 22:27 UTC

Acquisitions, Fusions, Rachats

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 mai 2026, 22:12 UTC

Résultats

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 mai 2026, 21:52 UTC

Acquisitions, Fusions, Rachats

LVMH to Sell Marc Jacobs

14 mai 2026, 23:57 UTC

Acquisitions, Fusions, Rachats

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 mai 2026, 23:56 UTC

Acquisitions, Fusions, Rachats

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 mai 2026, 23:56 UTC

Acquisitions, Fusions, Rachats

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 mai 2026, 23:56 UTC

Market Talk

Gold Prices Rise on Strong Demand -- Market Talk

14 mai 2026, 23:56 UTC

Acquisitions, Fusions, Rachats

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 mai 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

14 mai 2026, 23:50 UTC

Market Talk

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 mai 2026, 23:47 UTC

Résultats

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 mai 2026, 23:47 UTC

Résultats

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 mai 2026, 23:46 UTC

Résultats

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 mai 2026, 23:46 UTC

Résultats

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 mai 2026, 23:28 UTC

Market Talk

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 mai 2026, 23:00 UTC

Market Talk

Australia's One Nation Party Leads In The Polls -- Market Talk

14 mai 2026, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

14 mai 2026, 22:46 UTC

Market Talk

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 mai 2026, 22:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 mai 2026, 22:35 UTC

Market Talk

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 mai 2026, 22:11 UTC

Acquisitions, Fusions, Rachats

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 mai 2026, 22:06 UTC

Market Talk

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 mai 2026, 22:04 UTC

Résultats

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 mai 2026, 22:04 UTC

Résultats

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 mai 2026, 22:04 UTC

Résultats

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 mai 2026, 22:00 UTC

Résultats

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 mai 2026, 21:55 UTC

Résultats

Nu Holdings 1Q EPS 18c >NU

14 mai 2026, 21:55 UTC

Résultats

Nu Holdings 1Q Rev $4.97B >NU

14 mai 2026, 21:22 UTC

Acquisitions, Fusions, Rachats

G-III Apparel: Transaction Expected to Be Dilutive During First 12 Mos After Closing, With Accretion Expected Thereafter >GIII

Comparaison

Variation de prix

Adaptive Biotechnologies Corp prévision

Objectif de Prix

By TipRanks

47.91% hausse

Prévisions sur 12 Mois

Moyen 19.42 USD 47.91%

Haut 22 USD

Bas 13.54 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

Achat

Maintien

Vente

Basé sur 8 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

8.81 / 10.18Support & Résistance

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.